E. Erdal ERŞAN, SERPİL ERŞAN, Orhan DOĞAN

Şizofreni hastalarında plazma prostaglandin düzeyleri

Amaç: Şizofreni bireyi, aile üyelerini, toplumu etkileyen bir nöropsikiyatrik bozukluktur. Şizofreninin etiyopatogeneziyle ilgili birçok çalışma yapılmasına karşın, etiyopatogenezi tam olarak aydınlatılamamıştır. Bu çalışmada şizofreni hastalarında prostaglandin metabolit düzeylerinin ölçülmesi amaçlanmıştır. Yöntem: Çalışmaya yaş açısından eşleştirilmiş, cinsiyet ve sigara içme açısından benzer, en az iki yıldır hasta olan 50 şizofreni hastası ve 50 sağlıklı gönüllü alınmıştır. Çalışmamızda 13,14-dihidro-15-keto-PGF2α (PGFM) ve 13,14-dihidro-15-keto PGE2 (PGEM) ölçümü yapılmıştır. Ölçümler daha duyarlı bir aygıt olan High Perform Licid Chromatography (HPLC) ile yapıldı. İstatistiksel değerlendirmelerde Student’s t, Ki-kare, Kruskal-Wallis ve Mann-Whitney testi kullanılmıştır. PGEM düzeyi (0,0807±0.014’a karşı 0.0907±0.0146, t=3.490, p=0.001) ve PGFM düzeyi (0.0613±0.0128’e karşı 0.0793±0.0113, t=-7.486, p=0.000) hasta grubunda kontrol grubuna göre istatistiksel yönden anlamlı düzeyde düşük bulunmuştur. Tartışma: Bu sonuç şizofreninin etiyopatogenezinde fosfolipit metabolizmasındaki bir bozukluğun önemli olabileceğini düşündürmektedir

Prostaglandin metabolite levels in patients with schizophrenia

Objective: Schizophrenia is a neuropsychiatric disease which affects individuals, family members and society. Although many studies have been carried out on the etiopathogenesis of schizophrenia, the condition is not entirely understood. In this study, it has been aimed to measure prostaglandin (PG) metabolite levels in patients with schizophrenia. Methods: The present study measured prostaglandin metabolite levels in 50 schizophrenia patients and 50 healthy volunteers who were matched for age, sex and smoking is similar in terms of, at least two years of patient. Measurements were also taken of 13,14-dihydro-15-keto-PGF2α (PGFM) and 13,14-dihydro-15- keto PGE2 (PGEM). The measurements were performed using High Performance Liquid Chromatography (HPLC) which is a more sensitive device. Statistical analysis of the data was performed using Student’s t Test, Chi Square Test, Kruskal-Wallis Test and Mann-Whitney Test. Findings: In the patient group, the PGEM level (0.0807±0.014, t=3.490, p=0.001) and the PGFM level (0.0613±0.0128, t=-7.486, p=0.000) were both significantly lower than in the control group (PGEM 0.0907±0.0146; PGFM 0.0793±0.0113). Discussion: These results suggest that a disorder in phospholipid metabolism may be important in the etiopathogenesis of schizophrenia.

PDF

___

1. Ersoy İ. Biyokimya. Ankara, Türkiye Klinikleri, 1999.
2. Champe PC, Harvey AR. Biochemistry. Lippincot’s Illustrated Review, second ed., 1997, p.185-187.
3. Rose MR. Psychoendocrinology. TD Wilson, Foster (Eds.), Williams Textbook of Endocrinology, seventh ed., Philadelphia, WB Saunders, 1985, p.653-681.
4. Kayaalp O. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. On birinci baskı, 2. Cilt, Ankara, Feyral Matbaacılık, 2005, s.1279-1298.
5. Ebrinç S, Ceylan ME. Prostaglandinler. ME Ceylan, M Çetin (Eds.), Şizofreni, üçüncü baskı. İstanbul, Yerküre, 2005. s.553-563.
6. Sobell JL, Mikesell MJ, McMurray CT. Genetics and etiopathophysiology of schizophrenia. Mayo Clin Proc 2002; 77:1068-1082.
7. Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, et al. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res 1996; 21:111-116.
8. Christensen O, Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78:587-591.
9. Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid (letter). Arch Gen Psychiatry 1998; 55:188-189.
10. Peet M, Mellor J. Double-blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Presented at the 9th Schizophrenia Winter Workshop, Davos, Switzerland, 1998.
11. Tsaluchidu S, Cocchi M, Tonello L, Puri BK. Fatty acids and oxidative stress in psychiatric disorders. BMC Pschiatry 2008; 8(Suppl.1):S5.
12. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000; 47:8- 21.
13. Ross BM. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2003; 69:407-412.
14. Ruano D, Macedo A, Joao Soares M, Valente J, Helena Azevedo M, Pato C, et al. Family-based and casecontrol studies reveal no association of lipocalin-type prostaglandin D2 synthase with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007; 144B(5):642- 646.
15. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000; 42:7-17.
16. Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, et al. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res 2009; 169:91-96.
17. Bosetti F, Weerasinghe GR, Rosenberger TA, Rapoport SI. Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem 2003; 85:690-696.
18. Feldberg W. Possible association of schizophrenia with a disturbance in prostaglandin metabolism: a physiological hypothesis. Psychol Med 1976; 6:359-369.
19. Horrobin DF, Ally AI, Karmali RA, Karmazyn M, Manku MS, Morgan RO. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med 1978; 8:43-48.
20. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1(8018):936-937.
21. Heleniak E, O'Desky I. Histamine and prostaglandins in schizophrenia: revisited. Med Hypotheses 1999; 52:37- 42.
22. Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983; 40:405-406.
23. Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kunnunen PKJ. Increased plasma phospholipase-A activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatr 1987; 22:421-426.
24. Mathe AA, Sedvall G, Wiesel FA, Nyback H. Increased content of immunoreactive prostaglandin E in cerebrospinal fluid of patients with schizophrenia. Lancet 1980; 1(8158):16-18.
25. Gerner R, Merrill J. Cerebrospinal fluid prostaglandin E in depression, mania, and schizophrenia compared to normals. Biol Psychiatr 1983; 18:565-569.
26. Kaiya H, Uematsu M, Ofuji M, Nishida A, Takeuchi K, Nozaki M, Ideka E. Elevated plasma prostaglandin E2 levels in schizophrenia. J Neural Transm 1989; 77:39- 46.
27. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth ed., Text Revision (DSM-IV-TR), Washington, D.C., APA, 2000.
28. Samuelsson B. Isolation and identification of prostaglandins from human seminal plasma. 18. Prostaglandines and related factors. J Biol Chem 1963; 238:3229-3234.
29. Inayama S, Hori H, Shibata T. Simple and rapid separation of certain prostaglandins by reversed-phase high-performance liquid chromatography. J Chromatog 1980; 194:85-88.
30. Kaiya H. Prostaglandin E1 treatment of schizophrenia. Biol Psychiatry 1984; 19:457-463.
31. Kaiya H, Takai A, Morita K. Prostaglandin E1 treatment of schizophrenia. A second trial. GD Burrows, TR Norma (Eds.), Clinical and Pharmacological Studies in Psychiatric Disorders, London, John Libbey, 1985, p.202-210.
32. Nadalin S, Buretić-Tomljanović A, Rubesa G, Tomljanović D, Gudelj L. Niacin skin flush test: a research tool for studying schizophrenia. Psychiatr Danub 2010; 22:14-27.
33. Rudin DO. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry 1981; 16:837-850.
34. Mellor JE, Laugharne JDE, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids (letter to the editor). Schizophr Res 1995; 18:85-86.
35. Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins Leukotriene Essent Fatty Acids 1996; 55:71-75.
36. Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Presented at the 9th Schizophrenia Winter Workshop, Davos, 1998.